Choices in adjuvant therapy of melanoma (Q36301110)

13 August 2017

1 reference

title

Choices in adjuvant therapy of melanoma (English)

1 reference

13 August 2017

David H Lawson

1

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

12

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

236-241

1 reference

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Malignant melanoma: current state of primary and adjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Treatment at random: the ultimate science or the betrayal of Hippocrates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

Patient preferences for adjuvant interferon alfa-2b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200405

10.1177/107327480501200405

21 January 2018

Identifiers

DOI

0 references

1 reference